Voyager Therapeutics, Inc.

VYGRSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1640266

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$250.0M	$40.9M	$37.4M	$171.1M	$104.4M
Research and Development Expense	$92.2M	$60.8M	$73.8M	$108.8M	$119.7M
Operating Expenses	$128.0M	$91.7M	$111.0M	$143.7M	$156.1M
Operating Income (Loss)	$122.0M	-$50.8M	-$73.6M	$27.4M	-$51.7M
Nonoperating Income (Expense)	$11.7M	$4.4M	$2.4M	$9.4M	$8.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$133.7M	-$46.4M	-$71.2M	$36.7M	—
Income Tax Expense (Benefit)	$1.4M	$16.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$393.1M	$351.3M	$159.4M	$193.9M	$261.6M
Assets, Current	$276.8M	$319.7M	$124.5M	$136.7M	$197.8M
Cash and Cash Equivalents, at Carrying Value	$71.4M	$68.8M	$117.4M	$104.4M	$86.0M
Liabilities	$93.3M	$115.0M	$100.3M	$98.8M	$107.3M
Liabilities, Current	$49.8M	$64.5M	$72.6M	$51.0M	$26.8M
Accounts Payable, Current	$4.0M	$1.6M	$2.6M	$574.0K	$634.0K
Stockholders' Equity Attributable to Parent	$59.0M	$95.1M	$154.3M	$99.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$77.9M	-$12.5M	-$53.5M	-$96.7M	$48.7M
Net Cash Provided by (Used in) Investing Activities	-$141.6M	-$7.3M	$65.9M	$113.0M	-$90.5M
Net Cash Provided by (Used in) Financing Activities	$33.6M	$1.1M	$612.0K	$3.2M	$81.0M
Payments to Acquire Property, Plant, and Equipment	$3.3M	$2.5M	$1.6M	$12.1M	$7.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)